Enhancing nuclear translocation: Perspectives in inhaled corticosteroid therapy

Therapeutic Delivery

Volumn 6, Issue 4, 2015, Pages 443-451

  Hakim, Amir ^a   Usmani, Omar S ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Glucocorticoid receptor; Inhaled corticosteroids; Nuclear translocation

Indexed keywords

BUDESONIDE; CALRETICULIN; CELL NUCLEUS RECEPTOR; CORTICOSTEROID; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; LEPTOMYCIN B; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; BRONCHODILATING AGENT;

ASTHMA; CELL NUCLEUS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DRUG RECEPTOR BINDING; FORCED EXPIRATORY VOLUME; HUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR IMPORT; NUCLEAR PORE COMPLEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; ACTIVE TRANSPORT; BIOLOGICAL MODEL; COMBINATION DRUG THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ACTIVE TRANSPORT, CELL NUCLEUS; ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; BRONCHODILATOR AGENTS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; MODELS, BIOLOGICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, GLUCOCORTICOID;

EID: 84929755506     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.15.10     Document Type: Review

References (71)

1. Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 80(2), 89-95 (2010).
2. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176(6), 532-555 (2007).
3. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 34(1), 13-16 (2009).
4. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 342-344; discussioin 344 (2000).
5. Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 340(25), 1948-1953 (1999).
6. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320(7245), 1297-1303 (2000).
7. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353(9167), 1819-1823 (1999).
8. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 351(9105), 773-780 (1998).
9. Highland KB, Strange C, Heffner J E. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann. Intern. Med. 138(12), 969-973 (2003).
10. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 7, CD002991 (2012).
11. Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J. Allergy Clin. Immunol. 110(6 Suppl.), S261-S268 (2002).
12. Usmani OS, Ito K, Maneechotesuwan K et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 172(6), 704-712 (2005).
13. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344(8917), 219-224 (1994).
14. Haque R, Hakim A, Moodley T et al. Inhaled long-acting beta2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. J. Allergy Clin. Immunol. 132(5), 1166-1173 (2013).
15. Juniper EF, Svensson K, O'byrne PM et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur. Respir. J. 14(5), 1038-1043 (1999).
16. Woolcock A, Lundback B, Ringdal N, Jacques L A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 153(5), 1481-1488 (1996).
17. Mak JC, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J. Clin. Invest. 96(1), 99-106 (1995).
18. Eickelberg O, Roth M, Lorx R et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 274(2), 1005-1010 (1999).
19. Papakonstantinou E, Klagas I, Karakiulakis G et al. Steroids and beta2 Agonists Regulate Hyaluronan Metabolism in Asthma Airway Smooth Muscle Cells. Am. J. Respir. Cell. Mol. Biol. 47(6), 759-767 (2012).
20. Orsida BE, Ward C, Li X et al. Effect of a long-acting beta2-agonist over three months on airway wall vascular remodeling in asthma. Am. J. Respir. Crit. Care Med. 164(1), 117-121 (2001).
21. Li X, Ward C, Thien F et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am. J. Respir. Crit. Care Med. 160(5 Pt 1), 1493-1499 (1999).
22. Johnson M. Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 1(3), 200-206 (2004).
23. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390(6655), 88-91 (1997).
24. Mcdonnell J, Latif ML, Rees ES, Bevan NJ, Hill SJ. Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human beta2-adrenoceptor. Br. J. Pharmacol. 125(4), 717-726 (1998).
25. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 337(20), 1405-1411 (1997).
26. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356(8), 775-789 (2007).
27. Kadmiel M, Cidlowski J A. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol. Sci. 34(9), 518-530 (2013).
28. Beato M, Klug J. Steroid hormone receptors: an update. Hum. Reprod. Update 6(3), 225-236 (2000).
29. Whitfield GK, Jurutka PW, Haussler CA, Haussler MR. Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. J. Cell BioChem. 32-33(Suppl.), 110-122 (1999).
30. Deroo BJ, Rentsch C, Sampath S, Young J, Defranco DB, Archer TK. Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol. Cell. Biol. 22(12), 4113-4123 (2002).
31. Vandevyver S, Dejager L, Libert C. On the trail of the glucocorticoid receptor: into the nucleus and back. Traffic 13(3), 364-374 (2012).
32. Strahle U, Klock G, Schutz G. A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. Proc. Natl Acad. Sci. USA 84(22), 7871-7875 (1987).
33. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto K R. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324(5925), 407-410 (2009).
34. Voss TC, Schiltz RL, Sung MH et al. Dynamic exchange at regulatory elements during chromatin remodeling underlies assisted loading mechanism. Cell 146(4), 544-554 (2011).
35. Tchen CR, Martins JR, Paktiawal N, Perelli R, Saklatvala J, Clark AR. Glucocorticoid regulation of mouse and human dual specificity phosphatase 1 (DUSP1) genes: unusual cis-acting elements and unexpected evolutionary divergence. J. Biol. Chem. 285(4), 2642-2652 (2010).
36. Muzikar KA, Nickols NG, Dervan P B. Repression of DNAbinding dependent glucocorticoid receptor-mediated gene expression. Proc. Natl Acad. Sci. USA 106(39), 16598-16603 (2009).
37. Mckay LI, Cidlowski J A. Cross-talk between nuclear factorkappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol. Endocrinol. 12(1), 45-56 (1998).
38. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24(4), 488-522 (2003).
39. Heck S, Kullmann M, Gast A et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 13(17), 4087-4095 (1994).
40. Li MD, Ruan HB, Singh JP et al. O-GlcNAc transferase is involved in glucocorticoid receptor-mediated transrepression. J. Biol. Chem. 287(16), 12904-12912 (2012).
41. Barnes PJ. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 533(1-3), 2-14 (2006).
42. Barnes PJ. Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 163(1), 29-43 (2011).
43. Garside H, Stevens A, Farrow S et al. Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric effects on the glucocorticoid receptor DNA binding domain. J. Biol. Chem. 279(48), 50050-50059 (2004).
44. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 8(3), 183-192 (2008).
45. Ito K, Yamamura S, Essilfie-Quaye S et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203(1), 7-13 (2006).
46. Hakim A, Barnes PJ, Adcock IM, Usmani O S. Importin-7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity. FASEB J. 27(11), 4510-4519 (2013).
47. Galigniana MD, Echeverria PC, Erlejman AG, Piwien-Pilipuk G. Role of molecular chaperones and TPR-domain proteins in the cytoplasmic transport of steroid receptors and their passage through the nuclear pore. Nucleus 1(4), 299-308 (2010).
48. Freedman ND, Yamamoto K R. Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol. Biol. Cell 15(5), 2276-2286 (2004).
49. Savory JG, Hsu B, Laquian IR et al. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol. Cell. Biol. 19(2), 1025-1037 (1999).
50. Picard D, Yamamoto K R. Two signals mediate hormonedependent nuclear localization of the glucocorticoid receptor. EMBO J. 6(11), 3333-3340 (1987).
51. Cadepond F, Gasc JM, Delahaye F et al. Hormonal regulation of the nuclear localization signals of the human glucocorticosteroid receptor. Exp. Cell Res. 201(1), 99-108 (1992).
52. Raby BA, Van Steen K, Lasky-Su J, Tantisira K, Kaplan F, Weiss ST. Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma. Respir. Res. 10, 67 (2009).
53. Tao T, Lan J, Lukacs GL, Hache RJ, Kaplan F. Importin 13 regulates nuclear import of the glucocorticoid receptor in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 35(6), 668-680 (2006).
54. Nakielny S, Dreyfuss G. Transport of proteins and RNAs in and out of the nucleus. Cell 99(7), 677-690 (1999).
55. Strambio-De-Castillia C, Niepel M, Rout M P. The nuclear pore complex: bridging nuclear transport and gene regulation. Nat. Rev. Mol. Cell. Biol. 11(7), 490-501 (2010).
56. Poon IK, Jans DA. Regulation of nuclear transport: central role in development and transformation? Traffic 6(3), 173-186 (2005).
57. Wagstaff KM, Jans DA. Importins and beyond: non-conventional nuclear transport mechanisms. Traffic 10(9), 1188-1198 (2009).
58. Mendel DB, Bodwell JE, Gametchu B, Harrison RW, Munck A. Molybdate-stabilized nonactivated glucocorticoid-receptor complexes contain a 90-kDa non-steroid-binding phosphoprotein that is lost on activation. J. Biol. Chem. 261(8), 3758-3763 (1986).
59. Galigniana MD, Scruggs JL, Herrington J et al. Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton. Mol. Endocrinol. 12(12), 1903-1913 (1998).
60. Galigniana MD, Piwien-Pilipuk G, Assreuy J. Inhibition of glucocorticoid receptor binding by nitric oxide. Mol. Pharmacol. 55(2), 317-323 (1999).
61. Hawkins GA, Lazarus R, Smith RS et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 123(6), 1376-1383 e1377 (2009).
62. Ismaili N, Garabedian M J. Modulation of glucocorticoid receptor function via phosphorylation. Ann. NY Acad. Sci. 1024, 86-101 (2004).
63. Maeng S, Hunsberger JG, Pearson B et al. BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc. Natl Acad. Sci. USA 105(25), 8766-8771 (2008).
64. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H, Imai K. Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol. Endocrinol. 16(10), 2382-2392 (2002).
65. Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid BioChem. Mol. Biol. 102(1-5), 11-21 (2006).
66. Zhang Y, Leung DY, Goleva E. Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma. J. Allergy Clin. Immunol. 133(6), 1744-1752 e1741 (2014).
67. Nanzer AM, Chambers ES, Ryanna K et al. The effects of calcitriol treatment in glucocorticoid-resistant asthma. J. Allergy Clin. Immunol. 133(6), 1755-1757 e1754 (2014).
68. Holaska JM, Black BE, Love DC, Hanover JA, Leszyk J, Paschal BM. Calreticulin Is a receptor for nuclear export. J. Cell Biol. 152(1), 127-140 (2001).
69. Holaska JM, Black BE, Rastinejad F, Paschal B M. Ca2+-dependent nuclear export mediated by calreticulin. Mol. Cell. Biol. 22(17), 6286-6297 (2002).
70. Liu J, Defranco DB. Chromatin recycling of glucocorticoid receptors: implications for multiple roles of heat shock protein 90. Mol. Endocrinol. 13(3), 355-365 (1999).
71. Nachury MV, Weis K. The direction of transport through the nuclear pore can be inverted. Proc. Natl Acad. Sci. USA 96(17), 9622-9627 (1999).